To report the authors' experience with diagnosis and management of Dravet syndrome, or severe myoclonic epilepsy in infancy, in the era of commercially available genetic testing, the authors performed a retrospective study of 16 patients diagnosed with Dravet syndrome at a tertiary care pediatric epilepsy center. They analyzed their clinical presentation, electroencephalographic findings, genetic (SCN1A gene) results, and treatment responses and compared the findings to previous reports. The patients presented with all the previously described characteristics of Dravet syndrome. Six of the 7 patients (86%) who were tested for SCN1A mutations had positive results. The best treatment combinations included topiramate, valproate, or the ketogenic diet. Dravet syndrome is a well-defined epileptic syndrome that needs larger recognition, particularly because commercial testing for SCN1A gene mutations is now available in the United States. Despite its reputation for seizure intractability, several treatment options may be particularly helpful, whereas others need to be avoided.
Dravet C.Les épilepsies graves de l'enfant . Vie méd.1978; 8: 543-548 .
2.
Dravet C. , Bureau M. , Oguni H. , et al. Severe myoclonic epilepsy in infancy: Dravet syndrome . Adv Neurol.2005;95: 71-102 .
3.
Casse-Perrot C. , Wolf M. , Dravet C.Neuropsychological aspect of severe myoclonic epilepsy. In: Jambaque I , Lassonde M , Dulac O , eds. The Neuropsychology of Childhood Epilepsy. New York, NY: Plenum Press / Kluwer Academic ; 2001:131-140.
4.
Siegler Z. , Barsi P. , Neuwirth M. , et al. Hippocampal sclerosis in severe myoclonic epilepsy in infancy: a retrospective MRI study . Epilepsia. 2005 ;46: 704-708 .
5.
Singh R. , Andermann E. , Whitehouse WP , et al. Severe myoclonic epilepsy of infancy: extended spectrum of GEFS+?Epilepsia. 2001;42: 837-844 .
6.
Oguni H. , Hayashi K. , Osawa M. , et al. Severe myoclonic epilepsy in infancy: clinical analysis and relation to SCN1A mutations in a Japanese cohort . Adv Neurol.2005;95: 103-117 .
7.
Wakai S. , Ito N. , Sueoka H. , et al. Severe myoclonic epilepsy in infancy and carbamazepine . Eur J Pediatr.1996;155: 724 .
8.
Escayg A. , MacDonald BT , Meisler MH , et al. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2 . Nat Genet.2000;24: 343-345 .
9.
Wallace RH , Scheffer IE , Barnett S. , et al. Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus . Am J Hum Genet.2001;68: 859-865 .
10.
Claes L. , Del-Favero J. , Ceulemans B. , et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy . Am J Hum Genet.2001;68: 1327-1332 .
11.
Claes L. , Ceulemans B. , Audenaert D. , et al. De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy . Hum Mutat.2003;21: 615-621 .
12.
Fujiwara T. , Sugawara T. , Mazaki-Miyazaki E. , et al. Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures . Brain. 2003;126: 531-546 .
13.
Nabbout R. , Gennaro E. , Dalla Bernardina B. , et al. Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy . Neurology.2003;60: 1961-1967 .
14.
Annesi G. , Gambardella A. , Carrideo S. , et al. Two novel SCN1A missense mutations in generalized epilepsy with febrile seizure plus . Epilepsia. 2003;44: 1257-1258 .
15.
Sugawara T. , Mazaki-Miyazaki E. , Fukushima K. , et al. Frequent mutations of SCN1A in severe myoclonic epilepsy of infancy . Neurology. 2002; 58: 1122-1124 .
16.
Ohmori I. , Ouchida M. , Ohtsuka Y. , et al. Significant correlation of the SCN1A mutations and severe myoclonic epilepsy in infancy . Biochem Biophys Res Commun.2002;295: 17-23 .
17.
Fukuma G. , Oguni H. , Shirasaka Y. , et al. Mutations of neuronal voltage-gated Na+ channel α1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB) . Epilepsia.2004;45: 140-148 .
18.
Wallace RH , Hodgson BL , Grinton BE , et al. Sodium channel α1-subunit mutations in severe myoclonic epilepsy of infancy and infantile spasms . Neurology. 2003;61: 765-769 .
19.
Ohmori I. , OhtsukaY. , Ouchida M. , et al. Is phenotype difference in severe myoclonic epilepsy in infancy related to SCN1A mutations ? Brain Dev.2003 ;25: 488-493 .
20.
Chen Z. , Alcayaga C. , Suarez-Isla BA , et al. A “minimal” sodium channel construct consisting of ligated S5-P-S6 segments forms a toxin-activatable Ionophore . J Biol Chem.2002;277: 24653-24658 .
21.
Kanai K. , Hirose S. , Oguni H. , et al. Effect of localization of missense mutations in SCN1A on epilepsy phenotype severity . Neurology. 2004;63: 329-334 .
22.
Rhodes TH , Lossin C. , Vanoye CG , et al. Noninactivating voltage-gated sodium channels in severe myoclonic epilepsy of infancy . Proc Natl Acad Sci U S A. 2004;101: 11147-11152 .
23.
Harkin LA , Bowser DN , Dibbens LM , et al. Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus . Am J Hum Genet.2002;70: 530-536 .
24.
Madia F. , Gennaro E. , Cecconi M. , et al. No evidence of GABRG2 mutations in severe myoclonic epilepsy of infancy . Epilepsy Res.2003;53: 196-200 .
25.
Sankar R. , Wheless JW , Dravet C. , et al. Treatment of myoclonic epilepsies in infancy and early childhood . Adv Neurol.2005;95: 289-298 .
Ceulemans B. , Boel M. , Claes L. , et al. Severe myoclonic epilepsy in infancy: toward an optimal treatment . J Child Neurol.2004;19: 516-521 .
28.
Nieto-Barrera M. , Candau R. , Nieto-Jimenez M. , et al. Topiramate in the treatment of severe myoclonic epilepsy in infancy . Seizure. 2000 ;9: 590-594 .
29.
Coppola G. , Capovilla G. , Montagnini A. , et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial . Epilepsy Res.2002;49: 45-48 .
30.
Chiron C. , Marchand MC , Tran A. , et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial . Lancet. 2000;356: 1638-1642 .
31.
Thanh TN , Chiron C. , Dellatolas G. , et al. Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet's syndrome) . Arch Pediatr.2002;9: 1120-1127 .
32.
Fejerman N. , Caraballo R. , Cersosimo R.Ketogenic diet in patients with Dravet syndrome and myoclonic epilepsies in infancy and early childhood . Adv Neurol.2005;95: 299-305 .
33.
Panyiotopoulos CPEpileptic encephalopathies in infancy and early childhood. In: Panayiotopoulos CP , ed. The Epilepsies: Seizures, Syndromes and Management. Chipping Norton , UK: Bladon Medical ; 2005:137-197.
34.
Guerrini R. , Dravet C. , Genton P. , et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy . Epilepsia. 1998 ;39: 508-512 .
35.
Saito Y. , Oguni H. , Awaya Y. , et al. Phenytoin-induced choreoathetosis in patients with severe myoclonic epilepsy in infancy . Neuropediatrics.2001 ;32: 231-235 .
